2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
216
Active not recruiting
168
Recruiting
145
Unknown
72
Terminated
71
Withdrawn
44
Not yet recruiting
18
Suspended
3
Enrolling by invitation
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Thoracic
1
Conditions
Small Cell Lung Carcinoma
1
Neoplasms
1
Interventions
Cisplatin
9
Specimen Handling
7
Educational Status
7
Standard of Care
6
Interviews as Topic
6
Drug Therapy
6
Carboplatin
6
Blood Specimen Collection
6
Radiotherapy
5
Nivolumab
5
Chemoradiotherapy
5
Surgical Procedures, Operative
4
Paclitaxel
4
Oxaliplatin
4
Observation
4
Lenalidomide
4
Fluorouracil
4
Dexamethasone
4
pembrolizumab
3
lenvatinib
3
camrelizumab
3
Surveys and Questionnaires
3
Practice Guidelines as Topic
3
Patient Navigation
3
Methods
3
Magnetic Resonance Spectroscopy
3
Magnetic Resonance Imaging
3
Gemcitabine
3
Fluorodeoxyglucose F18
3
Exercise
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Enrolling by invitation
×
durvalumab
×
Clear all
NCT05303532
2026-05-19
ROSY-D
AstraZeneca
Phase 3
Enrolling by invitation
214 enrolled
NCT06419179
2025-05-20
GUIDANCE
University of Cologne
Phase 2
Enrolling by invitation
29 enrolled